Information on EC 1.3.1.98 - UDP-N-acetylmuramate dehydrogenase

Word Map on EC 1.3.1.98
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Specify your search results
Select one or more organisms in this record:
Show additional data
Do not include text mining results
Include (text mining) results (more...)
Include results (AMENDA + additional results, but less precise; more...)


The expected taxonomic range for this enzyme is: Eukaryota, Bacteria

EC NUMBER
COMMENTARY hide
1.3.1.98
-
RECOMMENDED NAME
GeneOntology No.
UDP-N-acetylmuramate dehydrogenase
-
REACTION
REACTION DIAGRAM
COMMENTARY hide
ORGANISM
UNIPROT
LITERATURE
UDP-N-acetyl-alpha-D-muramate + NADP+ = UDP-N-acetyl-3-O-(1-carboxyvinyl)-alpha-D-glucosamine + NADPH + H+
show the reaction diagram
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
oxidation
-
-
-
-
redox reaction
-
-
-
-
reduction
-
-
-
-
PATHWAY
BRENDA Link
KEGG Link
MetaCyc Link
Amino sugar and nucleotide sugar metabolism
-
-
Metabolic pathways
-
-
Peptidoglycan biosynthesis
-
-
UDP-N-acetylmuramoyl-pentapeptide biosynthesis I (meso-diaminopimelate containing)
-
-
UDP-N-acetylmuramoyl-pentapeptide biosynthesis II (lysine-containing)
-
-
peptidoglycan biosynthesis
-
-
SYSTEMATIC NAME
IUBMB Comments
UDP-N-acetyl-alpha-D-muramate:NADP+ oxidoreductase
A flavoprotein (FAD). NADH can to a lesser extent replace NADPH.
CAS REGISTRY NUMBER
COMMENTARY hide
39307-28-3
-
ORGANISM
COMMENTARY hide
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
-
-
-
Manually annotated by BRENDA team
NRC 492
-
-
Manually annotated by BRENDA team
strain GC 2242
-
-
Manually annotated by BRENDA team
strain GC 2242
-
-
Manually annotated by BRENDA team
strain GC 4560 imp
-
-
Manually annotated by BRENDA team
strain GC 1131
-
-
Manually annotated by BRENDA team
strain 0100993
-
-
Manually annotated by BRENDA team
strain GC 1894
-
-
Manually annotated by BRENDA team
-
UniProt
Manually annotated by BRENDA team
SUBSTRATE
PRODUCT                       
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
UDP-N-acetyl-3-O-(1-carboxyvinyl)-D-glucosamine + NADPH
UDP-N-acetyl-3-D-muramate + NADP+
show the reaction diagram
UDP-N-acetyl-3-O-(1-carboxyvinyl)-D-glucosamine + NADPH
UDP-N-acetylmuramate + NADP+
show the reaction diagram
UDP-N-acetylenolpyruvylglucosamine + NADPH
UDP-N-acetylmuramic acid + NADP+
show the reaction diagram
UDP-N-acetylenolpyruvylglucosamine + NADPH + H+
UDP-N-acetylmuramate + NADP+
show the reaction diagram
additional information
?
-
NATURAL SUBSTRATES
NATURAL PRODUCTS
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
UDP-N-acetyl-3-O-(1-carboxyvinyl)-D-glucosamine + NADPH
UDP-N-acetyl-3-D-muramate + NADP+
show the reaction diagram
UDP-N-acetyl-3-O-(1-carboxyvinyl)-D-glucosamine + NADPH
UDP-N-acetylmuramate + NADP+
show the reaction diagram
Q5SJC8
-
-
-
r
UDP-N-acetylenolpyruvylglucosamine + NADPH
UDP-N-acetylmuramic acid + NADP+
show the reaction diagram
additional information
?
-
COFACTOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
NADH
-
reductase activity with NADH is only 5% of that with NADPH
nicotinamide hypoxanthine dinucleotide phosphate
-
reduced form, active substrate
additional information
-
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
Tl+
-
affinity about 8 times greater than K+, activation in decreasing order: Tl+, K+, NH4+, Rb+, Li+, Na+
additional information
INHIBITORS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(4S)-1,2-bis(4-chlorophenyl)-5-[2-(2,4-difluorophenyl)-2-oxoethoxy]-4-methylpyrazolidin-3-one
-
1,2-bis(3,4-dichlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (3,4-dichlorophenyl)amide
1,2-bis(3,4-dichlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid 4-tolylamide
1,2-bis(3,4-dichlorophenyl)pyrazolidine-3,5-dione
1,2-bis(3-chlorophenyl)-3,5-dioxopyrazolidine-4-carboxylic acid (4-chlorophenyl)amide
1,2-bis(3-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (4-trifluoromethylphenyl)amide
1,2-bis(3-chlorophenyl)pyrazolidine-3,5-dione
1,2-bis(4-chlorophenyl)-3,5-dioxo-N-phenylpyrazolidine-4-carboxamide
1,2-bis(4-chlorophenyl)-4,4-bis(6-phenylhexyl)pyrazolidine-3,5-dione
-
1,2-bis(4-chlorophenyl)-4,4-bis[2-(2,4-difluorophenyl)-2-oxoethyl]pyrazolidine-3,5-dione
-
1,2-bis(4-chlorophenyl)-4-(2,4-dichlorobenzyl)pyrazolidine-3,5-dione
-
1,2-bis(4-chlorophenyl)-4-(2-ethylbutyl)pyrazolidine-3,5-dione
-
1,2-bis(4-chlorophenyl)-4-(2-phenylethyl)pyrazolidine-3,5-dione
-
1,2-bis(4-chlorophenyl)-4-(3,4-dichlorobenzoyl)-5-hydroxy-1,2-dihydropyrazol-3-one
1,2-bis(4-chlorophenyl)-4-(3-methoxybenzyl)pyrazolidine-3,5-dione
-
1,2-bis(4-chlorophenyl)-4-(3-oxo-3-phenylpropyl)pyrazolidine-3,5-dione
-
1,2-bis(4-chlorophenyl)-4-(3-phenylpropyl)pyrazolidine-3,5-dione
-
1,2-bis(4-chlorophenyl)-4-(4-oxo-4-phenylbutyl)pyrazolidine-3,5-dione
-
1,2-bis(4-chlorophenyl)-4-(4-phenylbutyl)pyrazolidine-3,5-dione
-
1,2-bis(4-chlorophenyl)-4-(5-phenylpentyl)pyrazolidine-3,5-dione
-
1,2-bis(4-chlorophenyl)-4-(6-phenylhexyl)pyrazolidine-3,5-dione
-
1,2-bis(4-chlorophenyl)-4-cyclohexanecarbonyl-5-hydroxy-1,2-dihydropyrazol-3-one
1,2-bis(4-chlorophenyl)-4-heptylpyrazolidine-3,5-dione
-
1,2-bis(4-chlorophenyl)-4-[2-(2,4-difluorophenyl)-2-oxoethyl]-4-methylpyrazolidine-3,5-dione
-
1,2-bis(4-chlorophenyl)-4-[2-(4-fluorophenyl)-2-oxoethyl]pyrazolidine-3,5-dione
-
1,2-bis(4-chlorophenyl)-4-[2-(diethylamino)ethyl]pyrazolidine-3,5-dione
-
1,2-bis(4-chlorophenyl)-4-[3-(trifluoromethyl)benzyl]pyrazolidine-3,5-dione
-
1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (1-naphthalen-2-ylethyl)amide
1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (2-chlorophenyl)amide
1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (3-chlorophenyl)amide
1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (3-trifluoromethylphenyl)amide
1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (4-chlorophenyl)amide
1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (4-cyanophenyl)amide
1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (4-hydroxyphenyl)amide
1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (4-methoxyphenyl)amide
1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (4-trifluoromethylphenyl)amide
1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid 2,4-dichlorobenzylamide
1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid 2-chlorobenzylamide
1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid 3,4-dichlorobenzylamide
1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid cyclohexylamide
1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid phenethylamide
1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid [1-(4-bromophenyl)ethyl]amide
1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid [4(3-(dimethylamino)propylcarbamoyl)-phenyl]amide
1,2-bis(4-chlorophenyl)-5-hydroxy-4-(4-methoxybenzoyl)-1,2-dihydropyrazol-3-one
1,2-bis(4-chlorophenyl)-5-hydroxy-4-(4-trifluoromethoxybenzoyl)-1,2-dihydropyrazol-3-one
1,2-bis(4-chlorophenyl)-5-hydroxy-4-(4-trifluoromethylbenzoyl)-1,2-dihydropyrazol-3-one
1,2-bis(4-chlorophenyl)-5-hydroxy-4-(thiophene-2-carbonyl)-1,2-dihydropyrazol-3-one
1,2-bis(4-chlorophenyl)-5-hydroxy-4-[2-(4-methoxyphenyl)acetyl]-1,2-dihydropyrazol-3-one
1,2-bis(4-chlorophenyl)pyrazolidine-3,5-dione
1,2-bis(4-fluorophenyl)pyrazolidine-3,5-dione
1,2-diphenylpyrazolidine-3,5-dione
3'-NADP+
-
noncompetitive with respect to NADPH
3-acetylpyridine adenine dinucleotide phosphate
-
oxidized form, competitive with respect to NADPH
4'-[[1,2-bis(4-chlorophenyl)-3,5-dioxopyrazolidin-4-yl]methyl]biphenyl-2-carbonitrile
-
4,4-bis[2-(benzyloxy)ethyl]-1,2-bis(4-chlorophenyl)pyrazolidine-3,5-dione
-
4-(2-chlorobenzyl)-1,2-bis(4-chlorophenyl)pyrazolidine-3,5-dione
-
4-(4-butoxybenzoyl)-1,2-bis(4-chlorophenyl)-5-hydroxy-1,2-dihydropyrazol-3-one
4-(4-chlorobenzoyl)1,2-bis(4-chlorophenyl)-5-hydroxy-1,2-dihydropyrazol-3-one
4-(biphenylyl-4-carbonyl)-1,2-bis(4-chlorophenyl)-5-hydroxy-1,2-dihydropyrazol-3-one
4-benzyl-1,2-bis(4-chlorophenyl)pyrazolidine-3,5-dione
-
4-[1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carbonyl]aminobenzoic acid
4-[1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carbonyl]aminobenzoic acid ethyl ester
4-[2-(benzyloxy)ethyl]-1,2-bis(4-chlorophenyl)-4-methylpyrazolidine-3,5-dione
-
4-[2-(benzyloxy)ethyl]-1,2-bis(4-chlorophenyl)pyrazolidine-3,5-dione
-
4-[2-(benzylsulfanyl)ethyl]-1,2-bis(4-chlorophenyl)pyrazolidine-3,5-dione
-
4-[2-[benzyl(ethyl)amino]ethyl]-1,2-bis(4-chlorophenyl)pyrazolidine-3,5-dione
-
4-[3,5-bis(trifluoromethyl)benzyl]-1,2-bis(4-chlorophenyl)pyrazolidine-3,5-dione
-
5-hydroxy-3-oxo-1,2-diphenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid (4-bromophenyl)amide
5-hydroxy-3-oxo-1,2-diphenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid (4-chlorophenyl)amide
5-hydroxy-3-oxo-1,2-diphenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid phenylamide
ADP
-
at high concentration, competitive with respect to NADPH
ADP-ribose
-
at high concentration, competitive with respect to NADPH
Ca2+
-
complete inhibition at 10 mM
guanidine hydrochloride
-
an exponential decrease in enzymatic activity from 100% to 20% is observed between 0 and 0.05 M, no activity is observed above 0.5 M
iodoacetamide
-
-
iodoacetate
-
-
Li+
-
slight, in presence of K+
Mg2+
-
markedly inhibits stimulatory effect of K+
Mn2+
-
markedly inhibits stimulatory effect of K+
N-ethylmaleimide
Na+
-
slight, in presence of K+
NADP+
NADPH
-
substrate inhibition at pH 7.0, Ki: 1.6 mM
nicotinamide 1,N6-ethenoadenine dinucleotide phosphate
-
oxidized form, noncompetitive with respect to NADPH
nicotinamide hypoxanthine dinucleotide phosphate
-
oxidized form, noncompetitive with respect to NADPH
p-chloromercuribenzoate
thio-NADP+
UDP
-
at high concentration, noncompetitive with respect to NADPH
UDP-N-acetyl-3-O-(1-carboxyvinyl)-D-glucosamine
-
substrate inhibition at pH 6, Ki 0.01 mM with 0.15 mM NADPH, weaker at more basic pH
Urea
-
no activity at 2.5 M
uridine diphospho-N-acetylglucosamine
-
at very high concentration, noncompetitive with respect to NADPH
uridine diphospho-N-acetylmuramic acid
-
uncompetitive with respect to NADPH
additional information
-
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.0016 - 0.079
NADPH
0.0065 - 0.089
UDP-N-acetyl-3-O-(1-carboxyvinyl)-D-glucosamine
0.001 - 0.0039
UDP-N-acetylenolpyruvylglucosamine
additional information
additional information
kinetics of recombinant wild-type and mutant enzymes
-
IC50 VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.05
(4S)-1,2-bis(4-chlorophenyl)-5-[2-(2,4-difluorophenyl)-2-oxoethoxy]-4-methylpyrazolidin-3-one
Mycobacterium tuberculosis
P9WJL9
pH and temperature not specified in the publication
0.0072
1,2-bis(4-chlorophenyl)-4,4-bis(6-phenylhexyl)pyrazolidine-3,5-dione
Mycobacterium tuberculosis
P9WJL9
pH and temperature not specified in the publication
0.0058
1,2-bis(4-chlorophenyl)-4,4-bis[2-(2,4-difluorophenyl)-2-oxoethyl]pyrazolidine-3,5-dione
Mycobacterium tuberculosis
P9WJL9
pH and temperature not specified in the publication
0.011
1,2-bis(4-chlorophenyl)-4-(2,4-dichlorobenzyl)pyrazolidine-3,5-dione
Mycobacterium tuberculosis
P9WJL9
pH and temperature not specified in the publication
0.05
1,2-bis(4-chlorophenyl)-4-(2-ethylbutyl)pyrazolidine-3,5-dione
Mycobacterium tuberculosis
P9WJL9
pH and temperature not specified in the publication
0.035 - 0.05
1,2-bis(4-chlorophenyl)-4-(2-phenylethyl)pyrazolidine-3,5-dione
0.05
1,2-bis(4-chlorophenyl)-4-(3-methoxybenzyl)pyrazolidine-3,5-dione
Mycobacterium tuberculosis
P9WJL9
pH and temperature not specified in the publication
0.013
1,2-bis(4-chlorophenyl)-4-(3-oxo-3-phenylpropyl)pyrazolidine-3,5-dione
Mycobacterium tuberculosis
P9WJL9
pH and temperature not specified in the publication
0.01
1,2-bis(4-chlorophenyl)-4-(3-phenylpropyl)pyrazolidine-3,5-dione
Mycobacterium tuberculosis
P9WJL9
pH and temperature not specified in the publication
0.01
1,2-bis(4-chlorophenyl)-4-(4-oxo-4-phenylbutyl)pyrazolidine-3,5-dione
Mycobacterium tuberculosis
P9WJL9
pH and temperature not specified in the publication
0.0056
1,2-bis(4-chlorophenyl)-4-(4-phenylbutyl)pyrazolidine-3,5-dione
Mycobacterium tuberculosis
P9WJL9
pH and temperature not specified in the publication
0.01
1,2-bis(4-chlorophenyl)-4-(5-phenylpentyl)pyrazolidine-3,5-dione
Mycobacterium tuberculosis
P9WJL9
pH and temperature not specified in the publication
0.0089
1,2-bis(4-chlorophenyl)-4-(6-phenylhexyl)pyrazolidine-3,5-dione
Mycobacterium tuberculosis
P9WJL9
pH and temperature not specified in the publication
0.042
1,2-bis(4-chlorophenyl)-4-heptylpyrazolidine-3,5-dione
Mycobacterium tuberculosis
P9WJL9
pH and temperature not specified in the publication
0.049
1,2-bis(4-chlorophenyl)-4-[2-(2,4-difluorophenyl)-2-oxoethyl]-4-methylpyrazolidine-3,5-dione
Mycobacterium tuberculosis
P9WJL9
pH and temperature not specified in the publication
0.0054
1,2-bis(4-chlorophenyl)-4-[2-(4-fluorophenyl)-2-oxoethyl]pyrazolidine-3,5-dione
Mycobacterium tuberculosis
P9WJL9
pH and temperature not specified in the publication
0.05
1,2-bis(4-chlorophenyl)-4-[2-(diethylamino)ethyl]pyrazolidine-3,5-dione
Mycobacterium tuberculosis
P9WJL9
pH and temperature not specified in the publication
0.018
1,2-bis(4-chlorophenyl)-4-[3-(trifluoromethyl)benzyl]pyrazolidine-3,5-dione
Mycobacterium tuberculosis
P9WJL9
pH and temperature not specified in the publication
0.011
4'-[[1,2-bis(4-chlorophenyl)-3,5-dioxopyrazolidin-4-yl]methyl]biphenyl-2-carbonitrile
Mycobacterium tuberculosis
P9WJL9
pH and temperature not specified in the publication
0.0072
4,4-bis[2-(benzyloxy)ethyl]-1,2-bis(4-chlorophenyl)pyrazolidine-3,5-dione
Mycobacterium tuberculosis
P9WJL9
pH and temperature not specified in the publication
0.05
4-(2-chlorobenzyl)-1,2-bis(4-chlorophenyl)pyrazolidine-3,5-dione
Mycobacterium tuberculosis
P9WJL9
pH and temperature not specified in the publication
0.05
4-benzyl-1,2-bis(4-chlorophenyl)pyrazolidine-3,5-dione
Mycobacterium tuberculosis
P9WJL9
pH and temperature not specified in the publication
0.02
4-[2-(benzyloxy)ethyl]-1,2-bis(4-chlorophenyl)-4-methylpyrazolidine-3,5-dione
Mycobacterium tuberculosis
P9WJL9
pH and temperature not specified in the publication
0.011
4-[2-(benzyloxy)ethyl]-1,2-bis(4-chlorophenyl)pyrazolidine-3,5-dione
Mycobacterium tuberculosis
P9WJL9
pH and temperature not specified in the publication
0.0052
4-[2-(benzylsulfanyl)ethyl]-1,2-bis(4-chlorophenyl)pyrazolidine-3,5-dione
Mycobacterium tuberculosis
P9WJL9
pH and temperature not specified in the publication
0.05
4-[2-[benzyl(ethyl)amino]ethyl]-1,2-bis(4-chlorophenyl)pyrazolidine-3,5-dione
Mycobacterium tuberculosis
P9WJL9
pH and temperature not specified in the publication
0.012
4-[3,5-bis(trifluoromethyl)benzyl]-1,2-bis(4-chlorophenyl)pyrazolidine-3,5-dione
Mycobacterium tuberculosis
P9WJL9
pH and temperature not specified in the publication
SPECIFIC ACTIVITY [µmol/min/mg]
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
additional information
-
pH OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
8.1 - 8.5
pH RANGE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
7.1 - 9.9
-
at pH 7.1 and pH 9.9 about 60% of maximal activity
7.8 - 8.4
-
-
TEMPERATURE OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
22
assay at room temperature
40
-
increase of activity up to 40°C
TEMPERATURE RANGE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
20 - 40
-
at 20 and 40°C more than 85% of the activity is retained
40 - 50
-
40°C: activity maximum, 50°C: about 30% of activity maximum
50
-
at 50°C about 30% of maximal activity
LOCALIZATION
ORGANISM
UNIPROT
COMMENTARY hide
GeneOntology No.
LITERATURE
SOURCE
PDB
SCOP
CATH
ORGANISM
UNIPROT
Bacillus licheniformis (strain ATCC 14580 / DSM 13 / JCM 2505 / NBRC 12200 / NCIMB 9375 / NRRL NRS-1264 / Gibson 46)
Escherichia coli (strain K12)
Escherichia coli (strain K12)
Escherichia coli (strain K12)
Escherichia coli (strain K12)
Escherichia coli (strain K12)
Listeria monocytogenes serovar 1/2a (strain ATCC BAA-679 / EGD-e)
Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv)
Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1)
Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1)
Thermus thermophilus (strain HB8 / ATCC 27634 / DSM 579)
Thermus thermophilus (strain HB8 / ATCC 27634 / DSM 579)
Vibrio cholerae serotype O1 (strain ATCC 39315 / El Tor Inaba N16961)
MOLECULAR WEIGHT
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
13500
-
1 * 21500 + 1 * 13500, SDS-PAGE
21500
-
1 * 21500 + 1 * 13500, SDS-PAGE
37800
-
x * 37800
37850
-
determined by cDNA sequence
38340
-
electrospray mass spectrometry of recombinant protein
40000
-
ESI mass spectrometry
SUBUNITS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
?
-
x * 37800
heterodimer
-
1 * 21500 + 1 * 13500, SDS-PAGE
monomer
additional information
Crystallization/COMMENTARY
ORGANISM
UNIPROT
LITERATURE
S229A mutant and wild-type MurB
-
sequence alignment with Escherichia coli structures, PDB entries 2Q85 and 2MBR, and modeling of structure as well as docking with N-acetylpyruvyl glucosamine
by sitting-drop vapour diffusion; purified recombinant His-tagged enzyme, 20 mg/ml protein in 20 mM HEPES, pH 7.5 5 mM 2-mercaptoethanol or DTT, 20°C, hanging drop vapour diffusion method, mixing with reservoir solution containing 0.1 M sodium cacodylate, pH 6.5, 15% PEG 8000, and 0.5 M (NH4)2SO4, 4 days, yellow plate-shaped crystals cryoprotected in 10% PEG 8000, 0.55 M (NH4)2SO4, 0.1 M sodium cacodylate, pH 6.5, 5 mM BME or DTT with 15% 2-methyl 2,4-pentanediol, X-ray diffraction structure determination and analysis at 2.3 A resolution, altered crystallization conditions were optimized using the purified selenomethionine-labeled MurB at 20 mg/ml, in complex with 10 mM enolpyruvyl-UDP-N-acetylglucosamine, in 1-2 weeks on grease-coated microbridges by mixing 5 ml Se-Met MurB and 5 ml reservoir solution containing 0.1 M sodium cacodylate, 9.75% PEG 8000, 0.55 M (NH4)2SO4, 20% DMSO, and 5 mM 2-mercaptoethanol and producing larger crystals, overview
-
purified recombinant MurB, hanging drop-vapor diffusion method, 0.001 ml of protein solution containing 20 mg/ml protein in 20 mM HEPES-NaOH, pH 7.5, is mixed with 0.001 ml of reservoir solution containing 100 mM MES-NaOH, pH 6.5, 18% w/v PEG 8000 and 200 mM CaCl2, equilibration against 1 ml of mother liquor, Se-Met substituted crystals are grown under the same conditions, while the substrate-complex crystals are grown in the presence of 25 mM substrate UDPGlcNAc, crystals appear within 8 h, X-ray difraction structure determination and analysis at 1.15-1.7 A resolution
pH STABILITY
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
8 - 10
-
any increase or decrease in pH from 8.0 results in significant drop in functional activity of the enzyme. Complete loss of activity occurs at pH 10.0
722410
TEMPERATURE STABILITY
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
4
-
the purified recombinant His-tagged enzyme is unstable at 4°C
40 - 60
-
between 40°C and 60°C a fast decrease in enzyme activity is observed and above 60°C activity is completely lost
GENERAL STABILITY
ORGANISM
UNIPROT
LITERATURE
dithiothreitol stabilizes
-
repeated freeze-thaw cycles inactivate the purified recombinant His-tagged enzyme
-
OXIDATION STABILITY
ORGANISM
UNIPROT
LITERATURE
very sensitive to oxidation, rapid loss of activity in absence of added dithiothreitol
-
286063
STORAGE STABILITY
ORGANISM
UNIPROT
LITERATURE
-20°C, 0.05 M Tris-HCl buffer, pH 8.0, 1 mM dithiothreitol, 30% glycerol, stable for over three months
-
-20°C, pH 8.0, presence of dithiothreitol, up to 2 months without loss of activity
-
-70°C, without loss in activity for several months
-
Purification/COMMENTARY
ORGANISM
UNIPROT
LITERATURE
ammonium sulfate precipitation, Q-Sepharose column chromatography, and Superdex 200 gel filtration
-
Ni-NTA agarose column chromatography
-
recombinant enzyme from strain BL21(DE3) by ammonium sulfate fractionation, hydrophobic interaction and ion exchange chromatography to homogeneity
-
recombinant His-tagged enzyme from Escherichia coli K12S by nickel affinity chromatography
-
recombinant MurB from Escherichia coli strain BL21(DE3)
recombinant wild-type and mutant enzymes from Escherichia coli strain BL21(DE3) to homogeneity, native wild-type enzyme from Staphylococcus aureus 10fold by ammonium sulfate precipitation and two steps of anion exchange chromatography
Cloned/COMMENTARY
ORGANISM
UNIPROT
LITERATURE
expressed in Escherichia coli and in host strain
expressed in Escherichia coli BL21(DE3) cells
-
expressed in Escherichia coli DH5alpha cells
-
expression of MurB in Escherichia coli strain BL21(DE3)
gene murB, expression of His-tagged enzyme in Escherichia coli K12S
-
gene murB, overexpression of wild-type and mutant enzymes in Escherichia coli strain BL21(DE3), functional complementation of murB-deficient, temperature-sensitive Staphylcoccus aureus mutant strain TS2901 by the wild-type enzyme, and enzyme mutants G67A, S70A, G69A, and R230A
overexpression in Escherichia coli XA90F'lacIQ1
-
overexpression in strain BL21(DE3)
-
overexpression of protein in Escherichia coli strain BL21(DE3)
-
overexpression of protein in Escherichia coli strain JM109
-
ENGINEERING
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
S229A
-
by site-directed mutagenesis
E275K
strong decrease in enzyme activity, thinner cell walls than wild type strain
E296A
site-directed mutagenesis, highly reduced activity compared to the wild-type enzyme, no complementation of murB-deficient, temperature-sensitive Staphylcoccus aureus mutant strain TS2901
G251D
strong decrease in enzyme activity, thinner cell walls than wild type strain
G67A
site-directed mutagenesis, functional complementation of murB-deficient, temperature-sensitive Staphylcoccus aureus mutant strain TS2901
G69A
site-directed mutagenesis, functional complementation of murB-deficient, temperature-sensitive Staphylcoccus aureus mutant strain TS2901
G78D
strong decrease in enzyme activity, thinner cell walls than wild type strain
H259A
site-directed mutagenesis, highly reduced activity compared to the wild-type enzyme, no complementation of murB-deficient, temperature-sensitive Staphylcoccus aureus mutant strain TS2901
N71A
site-directed mutagenesis, highly reduced activity compared to the wild-type enzyme, no complementation of murB-deficient, temperature-sensitive Staphylcoccus aureus mutant strain TS2901
R176A
site-directed mutagenesis, highly reduced activity compared to the wild-type enzyme, no complementation of murB-deficient, temperature-sensitive Staphylcoccus aureus mutant strain TS2901
R213A
site-directed mutagenesis, nearly inactive mutant, no complementation of murB-deficient, temperature-sensitive Staphylcoccus aureus mutant strain TS2901
R230A
site-directed mutagenesis, functional complementation of murB-deficient, temperature-sensitive Staphylcoccus aureus mutant strain TS2901
S226A
site-directed mutagenesis, highly reduced activity compared to the wild-type enzyme, no complementation of murB-deficient, temperature-sensitive Staphylcoccus aureus mutant strain TS2901
S243F
strong decrease in enzyme activity, thinner cell walls than wild type strain
S70A
site-directed mutagenesis, functional complementation of murB-deficient, temperature-sensitive Staphylcoccus aureus mutant strain TS2901
Y175F
site-directed mutagenesis, highly reduced activity compared to the wild-type enzyme, poor functional complementation of murB-deficient, temperature-sensitive Staphylcoccus aureus mutant strain TS2901
APPLICATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
medicine
computional design of 3-D structures of MurB enzymes and docking studies will provide highly useful information towards rational design of new tuberculosis drugs through experimental research design for further formulations as per pharmaceutical norms
Show AA Sequence (14785 entries)
Longer loading times are possible. Please use the Sequence Search for a specific query.